Poseida Therapeutics, Inc.
Clinical trials sponsored by Poseida Therapeutics, Inc., explained in plain language.
A clinical-stage biopharmaceutical company developing gene and cell therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New CAR-T therapy targets Tough-to-Treat lymphomas
Disease control OngoingThis early-stage study tests a new treatment called P-CD19CD20-ALLO1 for people with certain types of B-cell blood cancers that have come back or not responded to standard therapy. The treatment uses specially engineered immune cells from a healthy donor to attack cancer cells. T…
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cell therapy targets Hard-to-Treat myeloma
Disease control OngoingThis early-stage trial is testing a new therapy called P-BCMA-ALLO1 for people with multiple myeloma that has come back or not responded to standard treatments. The therapy uses donor immune cells that are engineered to find and attack myeloma cells. The main goals are to check s…
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
15-Year Follow-Up begins for myeloma cell therapy patients
Disease control OngoingThis study follows about 100 people with multiple myeloma who previously received an experimental cell therapy called P-BCMA-101. Researchers will monitor them for up to 15 years to see how safe and effective the treatment remains over time. A safety switch drug called rimiducid …
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Donor immune cells take on Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …
Phase: PHASE1 • Sponsor: Poseida Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC